Please click HERE to visit the study website and to connect directly with the study team.

This study investigates the use of gluten detection technologies combined with telemedicine to manage celiac disease in newly diagnosed adults. Celiac disease is a condition where the immune system reacts to gluten, a protein found in wheat, barley, and rye, damaging the small intestine. The purpose of the study is to see if these technologies can improve patient outcomes, such as mucosal recovery, when added to standard care.

Participants will be randomly assigned to either receive the standard care, including a one-time in-person dietitian session and telemedicine follow-ups, or the standard care plus gluten detection technology. The study will measure outcomes like mucosal recovery, gastrointestinal symptoms, diet adherence, and quality of life over a 12-month period. Gluten detection technologies, such as gluten immunogenic peptide kits, help patients monitor gluten exposure through urine tests, potentially improving their management of a gluten-free diet.

• Who can participate: Adults aged 18 to 75 years who have been diagnosed with celiac disease within 4 months and are not currently using gluten detection technology can participate. Participants must be willing to use gluten detection technology and have had an initial dietitian visit at one of the participating centers.
• Study details: Participants will either receive standard care or standard care plus gluten detection technology. They will use the technology to monitor gluten exposure and participate in telemedicine sessions to support dietary management.
• Study timelines: The study will last 12 months.